Influence of immunotherapy with interferon-alpha and the efficacy of interferon combined with dendritic therapy on renal cell carcinoma

我们检查了免疫疗法与细胞因子（IFN-α和IL-2）组合的功效以及免疫疗法对RCC患者中的宿主免疫的影响。我们发现，调节性T细胞导致在接受免疫治疗如顺铂治疗或非清髓性同种异体细胞治疗的受者中诱导负效应。我们还表明，靶向药物或树突状细胞治疗联合IFN-α给药是可行和安全的，该治疗有可能延长晚期RCC的进展时间。

We examined the efficacy of immunotherapy combined with cytokines (IFN-a and IL-2) and the impact of the immunotherapy on host immunity in RCC patients. We found that regulatory T cells result in inducing negative effect in recipients received with immunotherapy such as cytokine-therapy or nonmyeloablative allogeneic cell therapy. We also indicated that targeted drugs- or dendritic cells-therapy combined with IFN-a administration is feasible and safe, and the treatment has the potential for prolonging the time to progression in advanced RCC.